Targeted androgen pathway suppression in localized prostate cancer: a pilot study

What Was Tested

Researchers studied Goserelin in this randomized controlled trial publication.

Ligand-mediated activation of the androgen receptor (AR) is critical for prostate cancer (PCa) survival and proliferation.

The failure to completely ablate tissue androgens may limit suppression of PCa growth.

Who Took Part

PubMed indexes the participants as middle-aged adults, older adults and people over 80, men only.

Thirty-five men with intermediate/high-risk clinically localized PCa were randomly assigned to goserelin combined with dutasteride (ZD), bicalutamide and dutasteride (ZBD), or bicalutamide, dutasteride, and ketoconazole (ZBDK) for 3 months before prostatectomy.

Controls included patients receiving combined androgen blockade with luteinizing hormone-releasing hormone agonist and bicalutamide.

How the Study Was Run

The design is described as randomized and pilot.

The participants were allocated by chance, so the Goserelin group and the comparison group should start out alike.

It is described as a pilot, a small early test of whether a larger Goserelin study would be practical.

The timeline in the abstract includes 3 months.

The primary outcome measure was tissue dihydrotestosterone (DHT) concentration.

What Was Measured

The subject headings attached to it are 5-alpha Reductase Inhibitors, Androgen Antagonists, Androgen Receptor Antagonists, Androsterone, Anilides, Antineoplastic Agents, Hormonal and Antineoplastic Combined Chemotherapy Protocols.

What This Means in Plain Language

The paper is a randomized and pilot study of Goserelin over 3 months.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2014 (Journal of clinical oncology : official journal of the American Society of Clinical Oncology), a journal based in United States.

More context: the Goserelin compound page.